Időskori makuladegeneráció: vizsgálatok itt: Csehország
12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Where
- Prague
- Életkor
- 50 év and over
- People
- 272 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07441642 · EU 2025-523704-77-00 - 3. fázisTaking peopleA Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
- Where
- Mladá Boleslav, Ostrava, Prague, Prague 6
- Életkor
- 50 év and over
- People
- 250 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06847542 · EU 2024-516924-32-00 - 2/3. fázisTaking peopleA Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Where
- Prague, Prague 5
- Életkor
- 60 év and over
- People
- 274 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06635148 · EU 2022-500747-21-00 - 3. fázisTaking peopleStudy to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- Where
- Ostrava, Prague, Prague 6
- Életkor
- 50 év and over
- People
- 561 worldwide
- Run by
- AbbVie
See details and how to joinNCT07007065 · EU 2024-512298-28-00 - 3. fázisTaking peopleA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
- Where
- Mladá Boleslav, Náchod, Ostrava, Pardubice V, Plzen 23, Prague, Prague 5
- Életkor
- 50 év and over
- People
- 304 worldwide
- Run by
- Amgen
See details and how to joinNCT07614776 · EU 2025-523500-72-00 - 2/3. fázisNot yet taking people in CsehországA Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
- Where
- Ostrava, Pardubice V, Prague, Prague 5
- Életkor
- 65 év and over
- People
- 125 worldwide
- Run by
- Shenzhen Oculgen Biomedical Technology Co. Ltd.
See details and how to join2026-526648-11-00 · EU 2026-526648-11-00 - 2. fázisTaking peopleA Study in Adults With Geographic Atrophy
- Where
- Pardubice V, Prague, Prague 5
- Életkor
- 60 év and over
- People
- 300 worldwide
- Run by
- Sitala Bio LTD
See details and how to joinNCT07606365 · EU 2026-525738-40-00 - 2/3. fázisTaking peopleA clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
- Where
- Mladá Boleslav, Náchod, Ostrava, Prague, Prague 5
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Eyebiotech Limited
See details and how to join2025-524894-17-00 · EU 2025-524894-17-00 - 2. fázisTaking peopleStudy to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
- Where
- Náchod, Prague, Prague 5, Sokolov
- Életkor
- 55 év and over
- People
- 324 worldwide
- Run by
- ONL Therapeutics
See details and how to joinNCT06659445 · EU 2024-513174-22-00 - 2. fázisTaking peoplePhase 2 Study of ADX-038 in Participants With Geographic Atrophy
- Where
- Prague, Praha Klanovice
- Életkor
- 60 év and over
- People
- 240 worldwide
- Run by
- ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06990269 · EU 2025-521779-30-00 - 2/3. fázisTaking peopleA Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- Where
- Mladá Boleslav, Náchod, Prague
- Életkor
- 50 év and over
- People
- 960 worldwide
- Run by
- EyeBiotech Ltd.
See details and how to joinNCT07496567 - 4. fázisTaking peopleComparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
- Where
- Prague
- People
- 100
- Run by
- Faculty Hospital Kralovske Vinohrady
See details and how to joinNCT06875245